Literature DB >> 24915776

The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.

Rebecca Kesselring1, Annette Thiel2, Ralph Pries3, Stefan Fichtner-Feigl4, Stefan Brunner4, Philipp Seidel3, Karl-Ludwig Bruchhage3, Barbara Wollenberg5.   

Abstract

BACKGROUND: Membrane-bound complement restriction proteins (mCRPs) CD46, CD55 and CD59 enable tumour cells to evade complement dependent cytotoxicity and antibody-dependent killing mechanisms. But less is known about the role of these mCRPs in head and neck cancer.
METHODS: In this study we determined the expression of the mCRPs on head and neck squamous cell carcinoma (HNSCC) cell lines, on tumour tissue and TDLNs (tumour-draining lymph nodes) as well as on lymphocytes from HNSCC patients. The influence of the HNSCC microenvironment on the mCRP regulation was analysed using Flow Cytometry, Western blotting and small interfering RNAs (siRNA) transfection studies.
RESULTS: We examined the effects of the HNSCC tumour milieu on the expression levels of CD46, CD55 and CD59. We investigated the susceptibility of HNSCC cells to CDC (complement-dependent cytotoxicity) while silencing the mCRPs. Our results demonstrate a huge influence of the HNSCC tumour microenvironment on the regulation of mCRP expression and show a reciprocal regulation between the different mCRPs themselves.
CONCLUSIONS: In summary, our data indicate that HNSCC has evolved different strategies to evade complement attacks and that the tumour microenvironment leads to the enhancement of complement resistance of the surrounding tissue.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD46; CD55; CD59; Complement receptors; HNSCC; Head and neck cancer

Mesh:

Substances:

Year:  2014        PMID: 24915776     DOI: 10.1016/j.ejca.2014.05.005

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  23 in total

1.  Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study.

Authors:  Jinli Lv; Bo Zhu; Liang Zhang; Qichao Xie; Wenlei Zhuo
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  p53 regulates CD46 expression and measles virus infection in myeloma cells.

Authors:  Anne Lok; Geraldine Descamps; Benoit Tessoulin; David Chiron; Marion Eveillard; Catherine Godon; Yannick Le Bris; Astrid Vabret; Celine Bellanger; Laurent Maillet; Sophie Barillé-Nion; Marc Gregoire; Jean-François Fonteneau; Steven Le Gouill; Philippe Moreau; Frederic Tangy; Martine Amiot; Agnes Moreau-Aubry; Catherine Pellat-Deceunynck
Journal:  Blood Adv       Date:  2018-12-11

3.  Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions.

Authors:  Michelle L Miller; Olivera J Finn
Journal:  Methods Enzymol       Date:  2019-08-12       Impact factor: 1.600

4.  Identification of a transcriptomic signature with excellent survival prediction for squamous cell carcinoma of the cervix.

Authors:  John J Wallbillich; Paul Mh Tran; Shan Bai; Lynn Kh Tran; Ashok K Sharma; Sharad A Ghamande; Jin-Xiong She
Journal:  Am J Cancer Res       Date:  2020-05-01       Impact factor: 6.166

Review 5.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

6.  Identification of α1,2-fucosylated signaling and adhesion molecules in head and neck squamous cell carcinoma.

Authors:  Brittany Montesino; Agata Steenackers; Juan M Lozano; Geoffrey D Young; Nan Hu; Robert Sackstein; Kevin Brown Chandler
Journal:  Glycobiology       Date:  2022-04-21       Impact factor: 4.313

7.  The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.

Authors:  Anne Monks; Yingdong Zhao; Curtis Hose; Hossein Hamed; Julia Krushkal; Jianwen Fang; Dmitriy Sonkin; Alida Palmisano; Eric C Polley; Laura K Fogli; Mariam M Konaté; Sarah B Miller; Melanie A Simpson; Andrea Regier Voth; Ming-Chung Li; Erik Harris; Xiaolin Wu; John W Connelly; Annamaria Rapisarda; Beverly A Teicher; Richard Simon; James H Doroshow
Journal:  Cancer Res       Date:  2018-10-24       Impact factor: 12.701

Review 8.  Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.

Authors:  Simonetta Ausoni; Paolo Boscolo-Rizzo; Bhuvanesh Singh; Maria Cristina Da Mosto; Giacomo Spinato; Giancarlo Tirelli; Roberto Spinato; Giuseppe Azzarello
Journal:  Cancer Metastasis Rev       Date:  2016-09       Impact factor: 9.264

9.  CD55 is a HIF-2α marker with anti-adhesive and pro-invading properties in neuroblastoma.

Authors:  F Cimmino; M Avitabile; L Pezone; G Scalia; D Montanaro; M Andreozzi; L Terracciano; A Iolascon; M Capasso
Journal:  Oncogenesis       Date:  2016-04-04       Impact factor: 7.485

10.  The immunohistochemical analysis of membrane-bound CD55, CD59 and fluid-phase FH and FH-like complement inhibitors in cancers of ovary and corpus uteri origin.

Authors:  Lucyna Kapka-Skrzypczak; Ewa Wolinska; Grzegorz Szparecki; Magdalena Czajka; Maciej Skrzypczak
Journal:  Cent Eur J Immunol       Date:  2015-10-15       Impact factor: 2.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.